Search

Automatic code review (ACR), which can relieve the costs of manual inspection, is an indispensable and essential task in software engineering. To deal with ACR, existing work is to serialize the abstract syntax tree (AST). However, making sense of the whole AST with sequence encoding approach is a daunting task, mostly due to some redundant nodes in AST hinder the transmission of node information. Not to mention that the serialized representation is inadequate to grasp the information of tree structure in AST. In this paper, we first present a new large-scale Apache Automatic Code Review (AACR) dataset for ACR task since there is still no publicly available dataset in this task. The release of this dataset would push forward the research in this field. Based on it, we propose a novel Simplified AST based Graph Convolutional Network (SimAST-GCN) to deal with ACR task. Concretely, to improve the efficiency of node information dissemination, we first simplify the AST of code by deleting the redundant nodes that do not contain connection attributes, and thus deriving a Simplified AST. Then, we construct a relation graph for each code based on the Simplified AST to properly embody the relations among code fragments of the tree structure into the graph. Subsequently, in the light of the merit of graph structure, we explore a graph convolution networks architecture that follows an attention mechanism to leverage the crucial implications of code fragments to derive code representations. Finally, we exploit a simple but effective subtraction operation in the representations between the original and revised code, enabling the revised difference to be preferably learned for deciding the results of ACR. Experimental results on the AACR dataset illustrate that our proposed model outperforms the state-of-the-art methods., 15 pages

BACKGROUND: Hepatitis E virus (HEV) is a nonenveloped RNA virus causing Hepatitis E worldwide. An increasing transfusion transmission cases of HEV infections from asymptomatic blood donors which causing serious illnesses in immunosuppressed recipients have been reported in the past few years. China is one of the highly prevalent regions of HEV, it is important to evaluate the risk of HEV transmission from blood transfusion. METHODS: A total of 1864 serum samples from blood donors and demographic characteristics were randomly collected from Feb to Mar 2018 in Dali city. Anti-HEV IgG, IgM and IgA antibodies and HEV antigen were examined by enzyme-linked immunosorbent assay (ELISA). HEV RNA was detected by real-time PCR. Multivariable logistic regression modelling was used to examine risk factors associated with HEV prevalence.RESULTS: Overall, the positive rate of anti-HEV IgG, IgM, and IgA antibodies was 13.36% (249/1864), 1.13%(21/1864), and 1.82%(34/1864), respectively. However, none of the 1864 serum samples was detected as HEV antigen-positive nor HEV RNA positive. The positive rate of anti-HEV IgG antibody is high as 28.57% (2/7) in the donors with isolated elevated alanine aminotransferase (ALT). Females (16.69%) had a significantly higher HEV seroprevalence than males (13.04%) (odds ratio [OR]: 1.34 [95% CI, 1.02-1.75]). Other ethnic minority (24.32%) and Bai (18.85%) donors had a significantly higher HEV seroprevalence when compared to Han (12.21%) blood donors (odds ratio [OR], 2.25 [95% CI, 1.04-4.88] for other ethnic minority, 1.65 [95% CI, 1.24-2.19] for Bai). Conclusions: Dali, Yunnan province, China is an endemic region f of hepatitis E virus, and women, Bai and other ethnic minorities may be potential risk factors for hepatitis E virus infection.. The risk of transmission of hepatitis E virus through blood transfusion is relatively low, and the specific risk value needs to be further tested by expanding the sample size. Whether to formulate the strategy for HEV screening in blood center needed further researched.

Background and Objectives To prevent Treponema Pallidum (TP) transmission from blood transfusion, enzyme‐linked immunosorbent assay (EIA) for anti‐TP has been widely used in routine blood donation screening in China for many years. The aim of this study was to evaluate the performance of the Abbott CMIA assay for detection of anti‐TP in Chinese blood donors. Materials and methods A total of 2420 plasma samples, already routinely screened for anti‐TP by two different EIAs, from four blood Centers were tested for anti‐TP by Abbott CMIA. Subsequently, all samples with positive results by one or both EIAs and/or by Abbott CMIA were subjected to confirmatory testing (CT) using recombinant immunoblot assay (RIBA) or Treponema Pallidum particle agglutination assay (TPPA). TP infection was defined by a RIBA or TPPA positive. Results Compared with two EIAs strategy, Abbott CMIA showed a relatively best sensitivity as 98.80% (95% CI: 97.44%‐100.16%) and a relatively best specificity as 99.58% (95% CI: 99.30%‐99.85%), yielding the best consistency (99.49%) between anti‐TP CT results with the highest κ value of .98. Conclusion This is the first study to evaluate the performance of the Abbott CMIA assays for detection of syphilis in Chinese blood donors. Our results suggested that CMIA performed better than both EIAs, and implementation of CMIA replacing two different EIA reagents might help to further reduce the risk of transfusion‐transmitted TP infection, decrease unnecessary blood waste and loss of blood donors.

BACKGROUND Hepatitis C virus (HCV) is an important transfusion-transmitted virus with global significance. The objective of this study was to evaluate the HCV prevalence and incidence among Chinese blood donors from 2013 to 2016. STUDY DESIGN AND METHODS Whole blood and apheresis platelet donations collected from five Chinese blood centers from June 1, 2013, to December 31, 2016, were screened in parallel by two different enzyme-linked immunosorbent assays for anti-HIV 1/2, hepatitis B surface antigen, anti-HCV, and syphilis. Screening-reactive samples were further confirmed by western blot. Confirmatory positive rates among first-time and repeat donors were used to estimate the prevalence and incidence rates. Multivariable logistic regression modeling was used to examine factors associated with HCV infection. RESULTS A total of 1,276,544 donations were collected from five Chinese blood centers, of which an estimated 1203 were confirmed HCV positive. The overall HCV prevalence among first-time donors was 166.56 per 100,000 donors (95% confidence interval, 156.04-177.08). The HCV incidence rate was estimated to be 15.21 (95% confidence interval, 11.83-19.56) per 100,000 person-years among repeat donors. Multivariable logistic regression results showed that increased age, lower educational levels, ethnicity, and occupation were all important factors associated with HCV confirmatory status among first-time donors (p

Background and aim It is commonly noticed that chaotic and inefficient subgenotyping are universally used academically and clinically, a standardized HBV genotype/subgenotype classification criterion is urgently acquired. Sequence similarity, which was commonly used for the last three decades, should be upgraded by phylogenetic analysis in genotyping of recombinant-free HBV strains. Methods In this study, 4,429 HBV whole-genome sequences were employed to reconstruct the phylogeny of HBV using Bayesian inference. After excluding recombinant sequences, calculating partitioned evolutionary models, excluding recombinant sequences, reconstructing phylogenetic trees, and performing a correlation analysis of genetic distances, geographical distribution and serotypes, we systematically redefined the genotypes and subgenotypes of HBV. Results Compared to previous taxonomy, fourteen subgenotypes (A5-A7; B5-B9; C2-C4, C7; and D6-D7) were revised in the new standard. Now the HBV is divided into ten genotypes (A-J) and 24 subgenotypes (A1-A3; B1-B5; C1-C6; D1-D6; and F1-F4). Conclusion Our robust genotype/subgenotype new taxonomy has objectively re-molded the current shape of HBV classification. We believe that all future hepatitis B related researches or diagnosis will be benefited under the new HBV genotyping/subgenotyping standards.